<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Sydney_Australia_Entrepreneurship skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Sydney Australia/Entrepreneurship</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="navbar navbar-inverse navbar-fixed-top" style="margin-top:15px;"><DIV class="container"><DIV class="navbar-collapse collapse"><UL class="nav navbar-nav navbar-right"><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Team">Team </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Team">About Us</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Attributions">Attributions</A></LI></UL><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Design">Design </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Design">Project Design</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Applied_Design">Applied Design</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated">Integrated Human Practices</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Entrepreneurship">Entrepreneurship</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Patent_Law">Patent Law</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Description">Project </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Description">Description</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Experiments">Protocols</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Safety">Safety</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Notebook">Notebook</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Results">Results</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Demonstrate">Demonstrate</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Model">Model </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Model">Our Modelling</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Human_Practices">Communications </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/HP/Silver">Human Practices</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Engagement">Engagement</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Collaborations">Collaborations</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Interlab">Interlab</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Rate_My_Gel">Rate My Gel</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Parts">Parts </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Parts">Our Parts</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Composite_Part">Our Composite Parts</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Basic_Part">Our Basic Parts</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Improve">Part Improvement</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Medals">Medals </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Medals"> Medals</A></LI></DIV></DIV></DIV><DIV class="container-fluid" id="please"><DIV class="row content" id="please" align="center"><H1>An Open Source Business Model, Can It Work?</H1><DIV style="width:90%;margin:auto;"><P style="font-family:'Quicksand';font-size:20px;text-align:center;"> Throughout the duration of the iGEM competitions, we ended up <A href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated">talking</A> to several different people who gave us perspective on the reality of making our project into a small business. This included Mike from INCUBATE, a start-up company designed from University of Sydney students specifically, offering mentoring and initial capital for your work. Whilst he encouraged us to seriously consider making our insulin, particularly Winsulin, a commercial product – the primary goal of the project was to make our work OpenSource like the iGEM registry. He did however provide some insight into the standard business model.
 With this goal in our mind – we approached entrepreneurship slightly differently, rather evaluating the success of an open-source insulin product. Our primary means of determining its viability was through an analysis of the advantages of an open-source model, and how the market could be used to provide leverage for breaking into the market. This analysis is closely paired with <A href="https://2017.igem.org/Team:Sydney_Australia/Applied_Design">applied design</A> where we considered current market solutions and their alternatives. .</P></DIV><DIV class="panel-group"><DIV class="panel panel-default"><DIV class="panel-heading"><H4 class="panel-title"><A data-toggle="collapse" href="#collapse0" style="font-size:30px;">Open-Source Tools to Enable the Market</A></H4></DIV><DIV id="collapse0" class="panel-collapse collapse"><DIV class="panel-body cell_model"><P style="font-family:'Quicksand';font-size:20px;text-align:center;">Open-source research and development has revolutionized the technology sector and is quickly making its way into other markets, powered by its offers of new and unique ways to approach the monetisation of Intellectual Property (IP). 
The open source design and characterisation of genetic sequences for protein manufacturing is gaining popularity, especially as the advent of accessible methods of DNA synthesis has removed the major technical barrier to reverse engineering the work of others. Organisations such as iGEM are evidence of this, as they showcase the work of researchers, whilst businesses such as AddGene provide simple sharing of DNA backbones for a fee. Similarly, focus on the downstream requirements of protein expression optimization is already entering the open-source market, expanding the tools available to synthetic biologists with small budgets. On the other hand, manufacturing plant design and optimisation often remains unobtainable, held as trade-secrets rather than patented. The technologies behind high-efficiency protein manufacturing are rarely shared between agents in the market. Improved transparency within this industry would be to the benefit of all. 
We propose a radical model of pharmaceutical development, whereby investors may assist in the funding of both the development and set-up costs of a novel pharmaceutical, without the need of investing in a pharmaceutical company, via an open-source investment scheme.</P><P style="font-family:'Quicksand';font-size:20px;text-align:center;">Financial Tools
Potential investors that wish to contribute their funds to developing life-saving pharmaceuticals are currently forced to purchase stock in a major pharmaceutical company. We suggest that an alternative financial platform can be designed that offers investors the opportunity to fund the clinical trials of a novel open-source drug, pledging money alongside other potential investors until sufficient capital is obtained to proceed. In this scenario, rather than the return on IP contributing to a single pharmaceutical company's profit margin, it can instead be divided between clinical trial investors and the developer of the IP. 
In this case, Return-On-Investment (ROI) must scale with the relative risk of the drug not completing clinical trials, however, this may still be significantly less than the ROI expected by public corporations. Furthermore, some legal protection would have to be established to prevent manufacturing of approved open-source drugs without a return contribution being made to the investors that helped get it approved.  
An additional new financial tool could allow investors to direct their capital towards necessary manufacturing facilities for setup and GMP approval of new manufacturing facilities. These new “Open-source Factory” funds could be combined with public investment to better overcome the challenge of economies-of-scale. Just like the stock exchange and investment banks, the aim of these financial tools is to help the market respond more effectively.</P></DIV></DIV></DIV></DIV><DIV class="panel-group" id="peri_model"><DIV class="panel panel-default"><DIV class="panel-heading"><H4 class="panel-title"><A data-toggle="collapse" href="#collapse1" style="font-size:30px;">How We Could Enter the Market Now</A></H4></DIV><DIV id="collapse1" class="panel-collapse collapse"><DIV class="panel-body peri_model"><P style="font-family:'Quicksand';font-size:20px;text-align:center;">
    A more traditional approach for marketing insulin while utilising Open Source technology would be possible with sufficient capital. In our case, we propose a competitive advantage could be found through facilitating efficiency of distribution of Human Insulin and Analogues. [1]
The global pharmaceutical distribution market is a maze of intermediaries, each adding a small profit margin to the final price. In this environment we suggest there is potential to utilise 21st Century online markets to improve distribution models.
e.g. A click-and-mortar business that matches a diabetic’s insulin requirements to a specific wholesaler - cutting out all intermediaries and claiming a small portion of the profit margin.</P></DIV></DIV></DIV></DIV><DIV class="row" id="please" align="center"><H1>Barriers to Entry</H1><H1><P style="font-family:'Quicksand';font-size:20px;font-weight:normal;text-align:center;" class="content" align="center">When considering the potential of starting up a company, we considered the current barriers restricting those from entering.
Creating a competitive advantage requires a business to overcome the market barriers to entry, while retaining sufficient capital to survive a price war from competitors. Below are the barriers to entry faced by new Active Pharmaceutical Ingredient manufacturing firms, including a relative descriptor of the cost/skill permeability of the barrier;</P><DIV align="center"><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" style="border-collapse:collapse;mso-table-layout-alt:fixed;border:none;
 mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:1184;mso-padding-alt:
 0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:33.75pt"><TD width="175" valign="top" style="width:175.1pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:33.75pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Non-Financial
  Permeability /10</SPAN></B></P></TD><TD width="191" valign="top" style="width:191.4pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:33.75pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Expected Financial
  Cost ($US)</SPAN></B></P></TD><TD width="156" valign="top" style="width:155.75pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:33.75pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Scaling/Ongoing Cost?</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1;height:37.8pt"><TD width="772" colspan="4" valign="top" style="width:772.15pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:37.8pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:16.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#8FAADC;mso-themecolor:accent1;mso-themetint:153;mso-style-textfill-fill-color:
  #8FAADC;mso-style-textfill-fill-themecolor:accent1;mso-style-textfill-fill-alpha:
  100.0%;mso-style-textfill-fill-colortransforms:&quot;lumm=60000 lumo=40000&quot;;
  mso-fareast-language:EN-GB">Technical Barriers</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:2;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;color:black;mso-fareast-language:EN-GB">Open-source
  creation of a biosynthetic organism</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">8</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">5000</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">No</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;color:black;mso-fareast-language:EN-GB">Design and
  Engineering expertise required for fermentation/purification plant</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">8</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">10000</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">No</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;color:black;mso-fareast-language:EN-GB">Open
  Source Development of an insulin pump</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">8</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">10000</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">No</SPAN></P></TD></TR><TR style="mso-yfti-irow:5;height:37.8pt"><TD width="772" colspan="4" valign="top" style="width:772.15pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:37.8pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:16.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#F4B183;mso-themecolor:accent2;mso-themetint:153;mso-style-textfill-fill-color:
  #F4B183;mso-style-textfill-fill-themecolor:accent2;mso-style-textfill-fill-alpha:
  100.0%;mso-style-textfill-fill-colortransforms:&quot;lumm=60000 lumo=40000&quot;;
  mso-fareast-language:EN-GB">Cost Barriers</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:6;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Clinical Trials I-IV
  (for new analogue insulin)</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">8</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">~200 million</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">No</SPAN></P></TD></TR><TR style="mso-yfti-irow:7;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Biosimilar Clinical
  Trials (for new generic/generic analogue)</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">5</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">~100 million*</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">No</SPAN></P></TD></TR><TR style="mso-yfti-irow:8;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Fermentation/Purification
  Equipment and Testing (Small - Large Scale)</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">6</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">2 million - 200
  million</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Yes</SPAN></P></TD></TR><TR style="mso-yfti-irow:9;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Fermentation/Purification
  Plant (Small - Large Scale)</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">6</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">4 million - 400
  million</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Yes</SPAN></P></TD></TR><TR style="mso-yfti-irow:10;height:40.05pt"><TD width="522" nowrap="" colspan="3" valign="top" style="width:522.25pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:40.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">* Biosimilar clinical
  trials yet to have enough data to generate an average expense</SPAN></P></TD></TR><TR style="mso-yfti-irow:11;height:37.8pt"><TD width="772" colspan="4" valign="top" style="width:772.15pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:37.8pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:16.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#A9D18E;mso-themecolor:accent6;mso-themetint:153;mso-style-textfill-fill-color:
  #A9D18E;mso-style-textfill-fill-themecolor:accent6;mso-style-textfill-fill-alpha:
  100.0%;mso-style-textfill-fill-colortransforms:&quot;lumm=60000 lumo=40000&quot;;
  mso-fareast-language:EN-GB">Market Barriers</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:12;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;color:black;mso-fareast-language:EN-GB">Enormous
  existing contracts between governments and pharmaceutical companies can be
  used to leverage significant pressure to use a certain product in PBS
  schemes.</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">5</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">USA, Europe,
  Australia; ~100m+ to disturb the status quo. For most developing nations,
  price/efficacy will be the major determining factor.</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Yes</SPAN></P></TD></TR><TR style="mso-yfti-irow:13;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;color:black;mso-fareast-language:EN-GB">Economies
  of scale favours existing manufacturers. Any new market entrant would be
  vulnerable to a price war after investing significantly in setup.</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">6</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">^ See
  Fermentation/Purification Plant and Equipment Costs</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Yes</SPAN></P></TD></TR><TR style="mso-yfti-irow:14;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Existing distribution
  systems are largely owned by competition</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">4</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">10 million + dependent
  upon strategic partnerships</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Yes</SPAN></P></TD></TR><TR style="mso-yfti-irow:15;height:37.8pt"><TD width="772" colspan="4" valign="top" style="width:772.15pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:37.8pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:16.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#B49DE3;mso-fareast-language:EN-GB">Legal Barriers</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:16;height:15.75pt"><TD width="250" nowrap="" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;color:black;mso-fareast-language:EN-GB">Existing
  patents protecting analogue insulins</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">6</SPAN></P></TD><TD width="191" nowrap="" valign="top" style="width:191.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Litigation Risk</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Possibly</SPAN></P></TD></TR><TR style="mso-yfti-irow:17;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Existing patents
  protecting insulin manufacturing optimisations</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">6</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Litigation Risk</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Possibly</SPAN></P></TD></TR><TR style="mso-yfti-irow:18;mso-yfti-lastrow:yes;height:15.75pt"><TD width="250" valign="top" style="width:249.9pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Existing patents for
  insulin pump technologies</SPAN></P></TD><TD width="175" valign="top" style="width:175.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">6</SPAN></P></TD><TD width="191" valign="top" style="width:191.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Litigation Risk</SPAN></P></TD><TD width="156" valign="top" style="width:155.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;mso-fareast-language:EN-GB">Possibly</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><P class="MsoNormal"><O:P> </O:P></P></H1><H1>Estimated Start Up Costs</H1><P style="font-family:'Quicksand';font-size:16px;text-align:center;"> A recent publication described three new Canadian manufacturers of a scale that we could conceivably build[1]. Canada’s dollar is at parity with Australia, and provides an excellent model for start-ups in Oceania.

COMPANY A has created a biotherapeutic that repairs tissue, and needs to develop a facility with analytical and research facilities. 
COMPANY B manufactures native marine collagen and has built a manufacturing facility that comprises 80% GMP compliant working environments and 20% standard storage rooms
COMPANY C has an innovative new plant-based biotherapeutic manufacturing system that it is attempting upscale. The 10,000 ft2 greenhouse operates alongside a 4000 ft2 primary recovery suite where protein is recovered from biomass.</P><DIV class="WordSection1"><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="787" style="border-collapse:collapse;mso-table-layout-alt:fixed;
 border:none;mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:1184;
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:14.2pt"><TD width="12" rowspan="8" valign="top" style="width:11.8pt;border:none;border-right:
  solid windowtext 1.0pt;mso-border-left-alt:solid windowtext .5pt;mso-border-left-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#8FAADC;mso-themecolor:accent1;mso-themetint:153;mso-style-textfill-fill-color:
  #8FAADC;mso-style-textfill-fill-themecolor:accent1;mso-style-textfill-fill-alpha:
  100.0%;mso-style-textfill-fill-colortransforms:&quot;lumm=60000 lumo=40000&quot;;
  mso-fareast-language:EN-GB"><O:P> </O:P></SPAN></B></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#8FAADC;mso-themecolor:accent1;mso-themetint:153;mso-style-textfill-fill-color:
  #8FAADC;mso-style-textfill-fill-themecolor:accent1;mso-style-textfill-fill-alpha:
  100.0%;mso-style-textfill-fill-colortransforms:&quot;lumm=60000 lumo=40000&quot;;
  mso-fareast-language:EN-GB">Company A</SPAN></B></P></TD><TD width="12" rowspan="8" valign="top" style="width:11.8pt;border:none;border-right:
  solid windowtext 1.0pt;mso-border-left-alt:solid windowtext .5pt;mso-border-left-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#F4B183;mso-themecolor:accent2;mso-themetint:153;mso-style-textfill-fill-color:
  #F4B183;mso-style-textfill-fill-themecolor:accent2;mso-style-textfill-fill-alpha:
  100.0%;mso-style-textfill-fill-colortransforms:&quot;lumm=60000 lumo=40000&quot;;
  mso-fareast-language:EN-GB"><O:P> </O:P></SPAN></B></P></TD><TD width="151" nowrap="" valign="top" style="width:151.2pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#F4B183;mso-themecolor:accent2;mso-themetint:153;mso-style-textfill-fill-color:
  #F4B183;mso-style-textfill-fill-themecolor:accent2;mso-style-textfill-fill-alpha:
  100.0%;mso-style-textfill-fill-colortransforms:&quot;lumm=60000 lumo=40000&quot;;
  mso-fareast-language:EN-GB">Company B</SPAN></B></P></TD><TD width="12" rowspan="8" valign="top" style="width:11.8pt;border:none;border-right:
  solid windowtext 1.0pt;mso-border-left-alt:solid windowtext .5pt;mso-border-left-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#A9D18E;mso-themecolor:accent6;mso-themetint:153;mso-style-textfill-fill-color:
  #A9D18E;mso-style-textfill-fill-themecolor:accent6;mso-style-textfill-fill-alpha:
  100.0%;mso-style-textfill-fill-colortransforms:&quot;lumm=60000 lumo=40000&quot;;
  mso-fareast-language:EN-GB"><O:P> </O:P></SPAN></B></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:20.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:#A9D18E;mso-themecolor:accent6;mso-themetint:153;mso-style-textfill-fill-color:
  #A9D18E;mso-style-textfill-fill-themecolor:accent6;mso-style-textfill-fill-alpha:
  100.0%;mso-style-textfill-fill-colortransforms:&quot;lumm=60000 lumo=40000&quot;;
  mso-fareast-language:EN-GB">Company C</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1;height:18.9pt"><TD width="312" nowrap="" valign="top" style="width:11.0cm;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:18.9pt"><P class="MsoNormal"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:
  Arial;mso-fareast-language:EN-GB">Building Related Expenses</SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:18.9pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">4,000,000.00</SPAN></P></TD><TD width="151" nowrap="" valign="top" style="width:151.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:18.9pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">200,000.00</SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:18.9pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">1,800,000.00</SPAN></P></TD></TR><TR style="mso-yfti-irow:2;height:14.2pt"><TD width="312" nowrap="" valign="top" style="width:11.0cm;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:
  Arial;mso-fareast-language:EN-GB">Equipment + Installation</SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">1,000,000.00</SPAN></P></TD><TD width="151" nowrap="" valign="top" style="width:151.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">980,000.00</SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">300,000.00</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;height:14.2pt"><TD width="312" nowrap="" valign="top" style="width:11.0cm;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:
  Arial;mso-fareast-language:EN-GB">Engineering/Validation</SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">1,000,000.00</SPAN></P></TD><TD width="151" nowrap="" valign="top" style="width:151.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">250,000.00</SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">900,000.00</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;height:14.2pt"><TD width="312" nowrap="" valign="top" style="width:11.0cm;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:
  Arial;mso-fareast-language:EN-GB">Total ($CA)</SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">6,000,000.00</SPAN></P></TD><TD width="151" nowrap="" valign="top" style="width:151.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">1,430,000.00</SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">3,000,000.00</SPAN></P></TD></TR><TR style="mso-yfti-irow:5;height:14.2pt"><TD width="312" nowrap="" valign="top" style="width:11.0cm;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal"><B><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:
  Arial;mso-fareast-language:EN-GB">Total ($US)</SPAN></B></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:18.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">4,680,000.00</SPAN></B></P></TD><TD width="151" nowrap="" valign="top" style="width:151.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:18.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">1,115,400.00</SPAN></B></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:18.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">2,340,000.00</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:6;height:14.2pt"><TD width="312" nowrap="" valign="top" style="width:11.0cm;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:
  Arial;mso-fareast-language:EN-GB">Annual GMP Compliance + Operating Expense
  ($<SPAN class="GramE">CA)*</SPAN></SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  color:black;mso-fareast-language:EN-GB">925,000.00</SPAN></P></TD><TD width="151" nowrap="" valign="top" style="width:151.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">454,000.00</SPAN></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">720,000.00</SPAN></P></TD></TR><TR style="mso-yfti-irow:7;mso-yfti-lastrow:yes;height:35.6pt"><TD width="312" nowrap="" valign="top" style="width:11.0cm;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:35.6pt"><P class="MsoNormal"><B><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:
  Arial;mso-fareast-language:EN-GB">Annual GMP Compliance + Operating Expense
  ($<SPAN class="GramE">US)*</SPAN></SPAN></B></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:35.6pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">721,500.00</SPAN></B></P></TD><TD width="151" nowrap="" valign="top" style="width:151.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:35.6pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">354,120.00</SPAN></B></P></TD><TD width="144" nowrap="" valign="top" style="width:144.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:35.6pt"><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:Quicksand;
  mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;
  mso-fareast-language:EN-GB">561,600.00</SPAN></B></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal"><O:P> </O:P></P></DIV><P style="font-family:'Quicksand';font-size:20px;text-align:center;">Since a lot of these prices are dependent on how much GMP and Non-GMP approved space a manufactuer has, its quite hard to tell how much starting an insulin manufacturing plant would be. Furthermore, annual compliance and operating costs would (hopefully) be covered by revenue streams. 
However, As a result of realising these upfront, and continued costs, we've come to the understanding that developing a manufacturing plant on our own is not a viable option. Serious investment or an agreement with a current up and running manufactuer is rewuited.</P></DIV></DIV><DIV class="row" id="please"><DIV class="content" align="center"><H1>Associated Risks</H1><P style="font-family:'Quicksand';font-size:20px;text-align:center;">Alternatively, we could sit on our open-source IP and act as philanthropic agents attempting to simplify this complex market. It would not yield enormous income, nor attract wealthy investors - yet it may be a necessary cause to follow. The following SWOT analysis elucidates the Strengths and Weaknesses of this model as well as the Opportunities and Threats that the market might pose to it;</P><DIV class="col-xs-6"><H2>Risk Matrix</H2></DIV><DIV class="col-xs-6"><H2>Potential Risks for Our Model</H2><DIV class="WordSection1"><DIV style="overflow-x:auto;"><TABLE class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0" align="left" width="396" style="width:396.2pt;border-collapse:collapse;mso-yfti-tbllook:1184;
 mso-table-lspace:9.0pt;margin-left:6.0pt;mso-table-rspace:9.0pt;margin-right:
 6.0pt;mso-table-anchor-vertical:paragraph;mso-table-anchor-horizontal:page;
 mso-table-left:81.05pt;mso-table-top:-53.75pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  20.0pt;mso-bidi-font-size:16.0pt;font-family:Quicksand;mso-bidi-font-family:
  Arial;color:black;mso-fareast-language:EN-GB">Potential Risk</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black 1.0pt;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  20.0pt;mso-bidi-font-size:16.0pt;font-family:Quicksand;mso-bidi-font-family:
  Arial;color:black;mso-fareast-language:EN-GB">Risk Matrix</SPAN></P></TD></TR><TR style="mso-yfti-irow:1"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFBE45;
  padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Price war from competitors</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFBE45;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">9</SPAN></P></TD></TR><TR style="mso-yfti-irow:2"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFBE45;
  padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">GMP failure, dangerous product</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFBE45;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">10</SPAN></P></TD></TR><TR style="mso-yfti-irow:3"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#A8D08D;
  mso-background-themecolor:accent6;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Escape/Release of GMO organism</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#A8D08D;mso-background-themecolor:accent6;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">2</SPAN></P></TD></TR><TR style="mso-yfti-irow:4"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#A8D08D;
  mso-background-themecolor:accent6;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Manufacturing Injuries</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#A8D08D;mso-background-themecolor:accent6;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">2</SPAN></P></TD></TR><TR style="mso-yfti-irow:5"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFBE45;
  padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Insufficient Liquidity</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFBE45;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">8</SPAN></P></TD></TR><TR style="mso-yfti-irow:6"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFBE45;
  padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Exclusionary contracts prevent entrance to
  certain markets</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFBE45;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">7</SPAN></P></TD></TR><TR style="mso-yfti-irow:7"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFD966;
  mso-background-themecolor:accent4;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Cure for Diabetes</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFD966;mso-background-themecolor:accent4;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">5</SPAN></P></TD></TR><TR style="mso-yfti-irow:8"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFD966;
  mso-background-themecolor:accent4;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Superior Analogue enters market</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFD966;mso-background-themecolor:accent4;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">6</SPAN></P></TD></TR><TR style="mso-yfti-irow:9"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFD966;
  mso-background-themecolor:accent4;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Inefficient secretion pathway</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFD966;mso-background-themecolor:accent4;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">6</SPAN></P></TD></TR><TR style="mso-yfti-irow:10"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFD966;
  mso-background-themecolor:accent4;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Inefficient Purification</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFD966;mso-background-themecolor:accent4;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">6</SPAN></P></TD></TR><TR style="mso-yfti-irow:11"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#A8D08D;
  mso-background-themecolor:accent6;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Local - High Australian Wages</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#A8D08D;mso-background-themecolor:accent6;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">2</SPAN></P></TD></TR><TR style="mso-yfti-irow:12"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#A8D08D;
  mso-background-themecolor:accent6;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Carbon Emissions Target</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#A8D08D;mso-background-themecolor:accent6;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">2</SPAN></P></TD></TR><TR style="mso-yfti-irow:13"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#A8D08D;
  mso-background-themecolor:accent6;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Nickel-Agarose Price Inflation</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#A8D08D;mso-background-themecolor:accent6;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">2</SPAN></P></TD></TR><TR style="mso-yfti-irow:14"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#A8D08D;
  mso-background-themecolor:accent6;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Electricity Inflation</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#A8D08D;mso-background-themecolor:accent6;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">2</SPAN></P></TD></TR><TR style="mso-yfti-irow:15"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#A8D08D;
  mso-background-themecolor:accent6;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Competitive advertising</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#A8D08D;mso-background-themecolor:accent6;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">2</SPAN></P></TD></TR><TR style="mso-yfti-irow:16;height:23.0pt"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFBE45;
  padding:5.0pt 5.0pt 5.0pt 5.0pt;height:23.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Government overregulation</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFBE45;padding:5.0pt 5.0pt 5.0pt 5.0pt;height:23.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">8</SPAN></P></TD></TR><TR style="mso-yfti-irow:17;height:24.0pt"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFBE45;
  padding:5.0pt 5.0pt 5.0pt 5.0pt;height:24.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Economies of Scale</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFBE45;padding:5.0pt 5.0pt 5.0pt 5.0pt;height:24.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">9</SPAN></P></TD></TR><TR style="mso-yfti-irow:18"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFD966;
  mso-background-themecolor:accent4;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Natural Disaster</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFD966;mso-background-themecolor:accent4;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">4</SPAN></P></TD></TR><TR style="mso-yfti-irow:19"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFD966;
  mso-background-themecolor:accent4;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Manufactory Fire</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFD966;mso-background-themecolor:accent4;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">4</SPAN></P></TD></TR><TR style="mso-yfti-irow:20"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFD966;
  mso-background-themecolor:accent4;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Internal Corruption</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFD966;mso-background-themecolor:accent4;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">4</SPAN></P></TD></TR><TR style="mso-yfti-irow:21"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFD966;
  mso-background-themecolor:accent4;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Patent Infringement Lawsuits</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFD966;mso-background-themecolor:accent4;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">3</SPAN></P></TD></TR><TR style="mso-yfti-irow:22"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#A8D08D;
  mso-background-themecolor:accent6;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">High Employee Turnover</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#A8D08D;mso-background-themecolor:accent6;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">2</SPAN></P></TD></TR><TR style="mso-yfti-irow:23"><TD width="275" valign="top" style="width:274.7pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;background:#FFBE45;
  padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Export/Import Restrictions</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  background:#FFBE45;padding:5.0pt 5.0pt 5.0pt 5.0pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">8</SPAN></P></TD></TR><TR style="mso-yfti-irow:24;mso-yfti-lastrow:yes;height:33.15pt"><TD width="275" valign="top" style="width:274.7pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-alt:solid black 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;background:#FFD966;mso-background-themecolor:
  accent4;mso-background-themetint:153;padding:5.0pt 5.0pt 5.0pt 5.0pt;
  height:33.15pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">Unforeseen Circumstances</SPAN></P></TD><TD width="122" valign="top" style="width:121.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  mso-border-alt:solid black 1.0pt;mso-border-bottom-alt:solid windowtext .5pt;
  background:#FFD966;mso-background-themecolor:accent4;mso-background-themetint:
  153;padding:5.0pt 5.0pt 5.0pt 5.0pt;height:33.15pt"><P class="MsoNormal" align="center" style="text-align:center;mso-element:frame;
  mso-element-frame-hspace:9.0pt;mso-element-wrap:around;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:81.1pt;
  mso-element-top:-53.75pt;mso-height-rule:exactly"><SPAN style="font-size:
  16.0pt;font-family:Quicksand;mso-bidi-font-family:Arial;color:black;
  mso-fareast-language:EN-GB">5</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal"><SPAN style="font-family:&quot;Times New Roman&quot;;mso-fareast-font-family:
&quot;Times New Roman&quot;;mso-fareast-language:EN-GB"><O:P> </O:P></SPAN></P><P class="MsoNormal"><O:P> </O:P></P></DIV></DIV></DIV></DIV><DIV class="panel-group"><DIV class="panel panel-default"><DIV class="panel-heading"><H4 class="panel-title"><A data-toggle="collapse" href="#collapse029" style="font-size:30px;">What We're Up Against</A></H4></DIV><DIV id="collapse029" class="panel-collapse collapse"><DIV class="panel-body cell_model"><P style="font-family:'Quicksand';font-size:20px;text-align:center;">
The sheer scale of the insulin market (600m+ potential patients) allows economies of scale to play a major role in the competitiveness of individual players. Without enormous investment capital, any new manufacturing facility will be too small to make a significant impact on the insulin market and may be unable to produce at a low enough cost to survive. As such, if we were to choose to become insulin manufacturers - we would need enormous initial capital to have any impact on the market supply. 
Large-scale Manufacturing Facilities
Expected cost: Minimum of US$100m for a medium-scale facility [2]
Research and Development of Single-Chain Insulin Analogues:
Expected cost: Upwards of $US50m for initial approval. Ongoing expense of 20-25% annual operating costs to ensure compliance. [3]</P></DIV></DIV></DIV></DIV><DIV class="panel-group"><DIV class="panel panel-default"><DIV class="panel-heading"><H4 class="panel-title"><A data-toggle="collapse" href="#collapse030" style="font-size:30px;">Would Public Investment Help?</A></H4></DIV><DIV id="collapse030" class="panel-collapse collapse"><DIV class="panel-body cell_model"><P style="font-family:'Quicksand';font-size:20px;text-align:center;">
Governments provide a functional alternative to corporate manufacturing, as they can justify investment in research and manufacturing that offers a lower potential profit margin (or even a loss). Analysis of trends and forces within the international manufacturing market exemplifies two nations already investing heavily in expanding local insulin manufacturing. 
The Open Insulin project requires the backing and cooperation of national governments to truly demystify the insulin market. Once we’ve established ourselves as a possible alternative to the established pharmaceutical brands, a strategic alliance for public funding would be an ideal outcome. Diabetes mismanagement is an international health crisis, and it is within the best interest of national authorities to invest in programs such as ours. 
</P></DIV></DIV></DIV></DIV><DIV class="content" align="center" id="please"><H1> References</H1><H4><UL><LI style="font-family:'Quicksand';font-size:20px;text-align:center;">DODELET, J.-F. 2008. Construction and Start-Up Costs for Biomanufacturing Plants. BiopressInternational.</LI></UL></H4></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>